Carboplatin and weekly paclitaxel in non-small cell lung cancer patients unfit for or pretreated with chemotherapy

Anticancer Research

Volumn 25, Issue 3 C, 2005, Pages 2555-2559

  Numico, Gianmauro ^a   Colantonio, Ida ^a   Gasco, Milena ^a   Bertelli, Gianfilippo ^b   Garrone, Ornella ^a   Occelli, Marcella ^a   Fea, Elena ^a   Di Costanzo, Gianna ^a   Granetto, Cristina ^a   Heouaine, Abdelamid ^a   Russi, Elvio ^a   Merlano, Marco ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b SINGLETON HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Non small cell lung cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PATIENT COMPLIANCE;

EID: 22944482516     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke N et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000.
2. Hanna N, Shepherd FA, Fossella FV, Pereira FV, De Marinis F, von Pawel FV et al: Randomized phase III trial of Pemetrexed versus Docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004.
3. The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91: 66-72, 1999.
4. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicho M et al: Gemcitabine plus best supportive care vs best supportive care in inoperable non-small cell lung cancer. A randomized trial with quality of life as the primary outcome. Br J Cancer 83: 447-453, 2001.
5. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P et al: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 92: 1074-1080, 2000.
6. Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U et al: A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy - naive patients with metastatic or non-resectable localized non-small cell lung cancer. Lung Cancer 27(3): 145-157, 2000.
7. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM et al: Weekly, high-dose paclitaxel in advanced lung carcinoma. Cancer 97(10): 2480-2486, 2003.
8. Chang AY, Rubins J, Asbury R, Boros L and Hui LF: Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol 28(suppl 14): 10-13, 2001.
9. Alberola V, Cortesi E and Juan O: Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer. Crit Rev Oncol/Hematol 44: S31-S41, 2002.
10. Huisman C, Smit EF, Giaccone G and Postmus PE: Second-line chemotherapy in relapsing or refractory non-small cell lung cancer: a review. J Clin Oncol 18: 3722-3730, 2000.
11. Geels P, Eisenhauer E, Bezjak A, Zee B and Day A: Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18: 2395-2405, 2000.
12. Ramanath RK, Capozzoli MJ, Trump DL, Jacobs S and Belani CP: Escalating doses of weekly paclitaxel in combination with carboplatin: a phase I study in advanced malignancies. Proc Am Soc Clin Oncol 18: 166a (abstract 638), 1999.
13. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D et al: Multicenter, randomized trial for stage IIIB or IV non-small cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21: 2933-2939, 2003.
14. Cockroft D and Gault M: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976.
15. Juan O, Albert A, Ordono F, Casany R, Caranana V, Campos Jm et al: Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study. Jpn J Clin Oncol 32: 449-454, 2002.
16. Marchetti P, Urien S, Cappellini GA, Ronzino G and Ficorella C: Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol/Ematol 44: S3-S13, 2002.
17. Laack E, Dierlamm T, Knuffmann C, Popp J, Schmied B, Durk H et al: Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer. Lung Cancer 36(3): 303-307, 2002.
18. Kosmas C, Tsavaris N, Panopoulos C, Vadiaka M, Stavroyianni K, Kourelis T et al: Gemcitabine and vinorelbine as second-line therapy in non-small cell lung cancer after prior treatment with taxane + platinum-based regimens. Eur J Cancer 37(8): 972-978, 2001.
19. Murphy WK, Winn RJ, Huber M et al: Phase II of taxol in patients with non-small cell lung cancer who have failed platinum containing chemotherapy. Proc Am Soc Clin Oncol 13: 363a (abstract 1224), 1994.
20. Socinsky MA, Steagall A and Gillenwater H: Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer. Cancer Invest 17: 181-188, 1999.
21. Koumakis G, Demiri M, Barbounis V, Vassilomanolakis M, Gontikakis E, Pamouksoglou P et al: Is weekly paclitaxel superior to paclitaxel given every three weeks? Results of a phase II trial. Lung Cancer 35: 315-317, 2002.
22. Kies MS, Unger P, Gillenwater H, Smith S, Peterman A, Schell M et al: Second-line weekly paclitaxel in patients with advanced non-small cell lung cancer failing first-line carboplatin/paclitaxel. Proc Am Soc Clin Oncol 19: 504a (abstract 1971), 2000.
23. Juan Vidal O, Alberola V, Ordono F, Villaroya T, Sanchez R, Encinas A et al: Low-dose weekly paclitaxel in the treatment of unresectable or metastatic non-small cell lung cancer. Neurological and electrophysiological evaluation of neurotoxicity. Proc Am Soc Clin Oncol 20: 271b (abstract 2837), 2001.
24. Quock J, Dea G, Tanaka M, Gandara D, Lara P and Lau D: Premedication strategy for weekly paclitaxel. Cancer Invest 20: 666-672, 2002.